PharmaEngine (TWO:4162) — Stock Price
PharmaEngine (TWO:4162) is currently trading at NT$64.70 TWD, up 1.57% today. Over the past 52 weeks, shares have ranged between NT$53.00 and NT$78.00. This page tracks PharmaEngine's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 4162 company net worth.
PharmaEngine (4162) Stock Price Chart — Daily History & Trading Volume
The chart below tracks PharmaEngine's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
PharmaEngine Income Statement — Revenue, Profit & Earnings by Year
PharmaEngine's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | NT$2.52 Billion | NT$767.67 Million | NT$654.38 Million | NT$654.84 Million | NT$1.06 Billion |
| Cost of Revenue | NT$47.74 Million | NT$48.70 Million | NT$49.70 Million | NT$37.07 Million | NT$37.23 Million |
| Gross Profit | NT$2.48 Billion | NT$718.97 Million | NT$604.68 Million | NT$617.76 Million | NT$1.02 Billion |
| Research & Development | NT$267.02 Million | NT$310.28 Million | NT$181.88 Million | NT$136.89 Million | NT$95.73 Million |
| SG&A | NT$155.37 Million | NT$92.97 Million | NT$94.95 Million | NT$81.67 Million | NT$76.23 Million |
| Total Operating Expenses | NT$470.14 Million | NT$441.79 Million | NT$321.94 Million | NT$255.29 Million | NT$209.07 Million |
| Operating Income | NT$2.05 Billion | NT$277.18 Million | NT$392.55 Million | NT$545.39 Million | NT$752.92 Million |
| EBITDA | — | NT$286.20 Million | NT$401.16 Million | NT$555.65 Million | NT$765.48 Million |
| EBIT | — | NT$277.18 Million | NT$392.55 Million | NT$545.39 Million | NT$752.92 Million |
| Interest Expense | NT$181.00K | NT$310.00K | NT$77.00K | NT$212.00K | NT$443.00K |
| Income Before Tax | NT$2.16 Billion | NT$337.97 Million | NT$392.46 Million | NT$545.39 Million | NT$752.48 Million |
| Income Tax Expense | — | NT$63.32 Million | NT$73.68 Million | NT$119.36 Million | NT$148.19 Million |
| Net Income | NT$1.75 Billion | NT$274.65 Million | NT$318.78 Million | NT$426.03 Million | NT$604.28 Million |
PharmaEngine Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes PharmaEngine's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | NT$5.85 Billion | NT$3.95 Billion | NT$3.97 Billion | NT$4.03 Billion | NT$4.21 Billion |
| Total Current Assets | NT$5.83 Billion | NT$3.92 Billion | NT$3.93 Billion | NT$4.01 Billion | NT$4.17 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$2.87 Billion | NT$2.75 Billion | NT$1.89 Billion | NT$1.66 Billion | NT$1.56 Billion |
| Net Receivables | NT$71.66 Million | NT$271.58 Million | NT$223.85 Million | NT$189.79 Million | NT$750.90 Million |
| Inventory | NT$28.38 Million | NT$15.90 Million | NT$34.38 Million | NT$5.43 Million | NT$24.74 Million |
| Property, Plant & Equipment | — | — | NT$25.92 Million | NT$7.89 Million | NT$22.95 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$448.01 Million | NT$91.01 Million | NT$94.47 Million | NT$87.70 Million | NT$195.78 Million |
| Total Current Liabilities | NT$443.05 Million | NT$83.86 Million | NT$78.74 Million | NT$87.70 Million | NT$184.46 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | NT$-860.81 Million | NT$-1.75 Billion | NT$-2.14 Billion | NT$-1.81 Billion |
| Total Stockholder Equity | NT$5.40 Billion | NT$3.86 Billion | NT$3.87 Billion | NT$3.94 Billion | NT$4.01 Billion |
| Retained Earnings | NT$2.13 Billion | NT$623.44 Million | NT$658.20 Million | NT$863.93 Million | NT$861.94 Million |
PharmaEngine Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how PharmaEngine generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$456.73 Million | NT$256.97 Million | NT$202.01 Million | NT$929.67 Million | NT$64.77 Million |
| Capital Expenditures | NT$1.42 Million | NT$958.00K | NT$3.94 Million | NT$229.00K | NT$608.00K |
| Free Cash Flow | NT$455.32 Million | NT$256.01 Million | NT$198.07 Million | NT$929.44 Million | NT$64.16 Million |
| Investing Cash Flow | — | — | NT$-188.12 Million | NT$-107.00 Million | NT$1.76 Billion |
| Financing Cash Flow | — | NT$-294.73 Million | NT$-395.71 Million | NT$-507.00 Million | NT$-87.50 Million |
| Dividends Paid | NT$215.44 Million | NT$287.19 Million | NT$387.71 Million | NT$363.99 Million | NT$72.83 Million |
| Stock-Based Compensation | NT$1.30 Million | NT$3.38 Million | NT$2.37 Million | NT$89.00K | NT$-1.05 Million |
| Depreciation | NT$9.31 Million | NT$9.02 Million | NT$8.61 Million | NT$10.26 Million | NT$12.56 Million |
| Change in Cash | NT$118.08 Million | NT$-893.24 Million | NT$-381.81 Million | NT$314.93 Million | NT$1.74 Billion |
PharmaEngine Earnings History — EPS Actual vs. Analyst Estimates
Track PharmaEngine's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 27, 2026 | — | — | — |
| Nov 11, 2025 | 0.95 | 0.94 | +1.06% |
| Aug 11, 2025 | 0.12 | 0.69 | -82.61% |
| Apr 23, 2025 | 0.71 | 0.54 | +31.48% |
| Feb 27, 2025 | 9.86 | 4.17 | +136.45% |
| Nov 07, 2024 | 0.64 | 0.65 | -1.54% |
| Aug 05, 2024 | 1.11 | 0.82 | +35.37% |
| Apr 25, 2024 | 0.57 | 0.49 | +16.33% |